AU2020343725B2 - Cancer treatment - Google Patents
Cancer treatmentInfo
- Publication number
- AU2020343725B2 AU2020343725B2 AU2020343725A AU2020343725A AU2020343725B2 AU 2020343725 B2 AU2020343725 B2 AU 2020343725B2 AU 2020343725 A AU2020343725 A AU 2020343725A AU 2020343725 A AU2020343725 A AU 2020343725A AU 2020343725 B2 AU2020343725 B2 AU 2020343725B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- cancer
- group
- amino acid
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019903263 | 2019-09-04 | ||
| AU2019903263A AU2019903263A0 (en) | 2019-09-04 | Cancer treatment | |
| AU2019904863A AU2019904863A0 (en) | 2019-12-20 | Cancer treatment (2) | |
| AU2019904863 | 2019-12-20 | ||
| PCT/AU2020/050936 WO2021042174A1 (en) | 2019-09-04 | 2020-09-04 | Cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020343725A1 AU2020343725A1 (en) | 2022-03-24 |
| AU2020343725B2 true AU2020343725B2 (en) | 2026-07-16 |
Family
ID=74851931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020343725A Active AU2020343725B2 (en) | 2019-09-04 | 2020-09-04 | Cancer treatment |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220347146A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4025203A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7862297B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020343725B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021042174A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2811957C (en) | 2010-09-22 | 2019-04-16 | The University Of Melbourne | Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents |
| IL275360B2 (en) | 2017-12-21 | 2023-10-01 | Axelia Oncology Pty Ltd | Optimal compounds |
| NZ783377A (en) | 2019-06-26 | 2026-03-27 | Ena Respiratory Pty Ltd | Pegylated novel molecules for agonising tlr2 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012037612A1 (en) * | 2010-09-22 | 2012-03-29 | The University Of Melbourne | Novel immunostimulatory method |
| WO2018176099A1 (en) * | 2017-03-31 | 2018-10-04 | Ena Therapeutics Pty Ltd | Treatment of respiratory infection with a tlr2 agonist |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1861426A4 (en) * | 2005-02-08 | 2008-11-12 | Queensland Inst Med Res | IMMUNOGENOUS MOLECULES |
| GB0907989D0 (en) * | 2009-05-08 | 2009-06-24 | Hybrid Systems Ltd | Multivalent adjuvant display |
| IN2014CN02581A (cg-RX-API-DMAC7.html) * | 2011-10-06 | 2015-08-07 | Immunovaccine Technologies Inc | |
| US20170274068A1 (en) * | 2014-09-12 | 2017-09-28 | The University Of Melbourne | Immunological reagent |
| EP3328418A1 (en) * | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| IL275360B2 (en) * | 2017-12-21 | 2023-10-01 | Axelia Oncology Pty Ltd | Optimal compounds |
| JP2022546806A (ja) * | 2019-09-04 | 2022-11-09 | アクセリア オンコロジー ピーティーワイ リミテッド | 癌免疫療法 |
-
2020
- 2020-09-04 WO PCT/AU2020/050936 patent/WO2021042174A1/en not_active Ceased
- 2020-09-04 US US17/640,714 patent/US20220347146A1/en active Pending
- 2020-09-04 JP JP2022513249A patent/JP7862297B2/ja active Active
- 2020-09-04 EP EP20859699.9A patent/EP4025203A4/en active Pending
- 2020-09-04 AU AU2020343725A patent/AU2020343725B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012037612A1 (en) * | 2010-09-22 | 2012-03-29 | The University Of Melbourne | Novel immunostimulatory method |
| WO2018176099A1 (en) * | 2017-03-31 | 2018-10-04 | Ena Therapeutics Pty Ltd | Treatment of respiratory infection with a tlr2 agonist |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4025203A1 (en) | 2022-07-13 |
| US20220347146A1 (en) | 2022-11-03 |
| EP4025203A4 (en) | 2023-12-20 |
| AU2020343725A1 (en) | 2022-03-24 |
| JP2022546807A (ja) | 2022-11-09 |
| WO2021042174A1 (en) | 2021-03-11 |
| JP7862297B2 (ja) | 2026-05-19 |